Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma

Journal of Clinical Oncology

Volumn 26, Issue 26, 2008, Pages 4296-4303

  Gershenwald, Jeffrey E ^a   Andtbacka, Robert H I ^a   Prieto, Victor G ^a   Johnson, Marcella M ^a   Diwan, A Hafeez ^a   Lee, Jeffrey E ^a   Mansfield, Paul F ^a   Cormier, Janice N ^a   Schacherer, Christopher W ^a   Ross, Merrick I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICROSCOPY; MORBIDITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SENTINEL LYMPH NODE; TIME SERIES ANALYSIS; TUMOR VOLUME; UNIVARIATE ANALYSIS; LYMPH NODE METASTASIS; MIDDLE AGED; PREDICTION AND FORECASTING; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 52049107850     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.4179     Document Type: Article

References (58)

1. Gershenwald J, Thompson W, Mansfield P, et al: Multi-institutional lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983, 1999
2. Gershenwald JE, Tseng CH, Thompson W, et al: Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124:203-210, 1998
3. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992
4. Morton DL, Thompson JF, Essner R, et al: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial: Multi-center Selective Lymphadenectomy Trial Group. Ann Surg 230:453-463, 1999
5. Ross M, Reintgen D, Balch C: Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9:219-223, 1993
6. Clary BM, Brady MS, Lewis JJ, et al: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 233:250-258, 2001
7. Dessureault S, Soong SJ, Ross Ml, et al: Improved staging of node-negative patients with intermediate to thick melanomas (> 1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8:766-770, 2001
8. Cochran AJ, Wen DR, Huang RR, et al: Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17: 747-755, 2004
9. Wagner J, Davidson D, Coleman I, et al: Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol 6:398-404, 1999
10. Wagner JD, Gordon MS, Chuang TY, et al: Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89:453-462, 2000
11. Essner R, Conforti A, Kelley MC, et al: Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 6:442-449, 1999
12. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factor analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
13. Cascinelli N, Morabito A, Santinami M, et al: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. Lancet 351:793-796, 1998
14. Kretschmer L, Hilgers R, Mohrle M, et al: Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 40:212-218, 2004
15. Schijven MP, Vingerhoets AJ, Rutten HJ, et al: Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 29:341-350, 2003
16. Golshan M, Martin WJ, Dowlatshahi K: Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am Surg 69:209-211, 2003
17. Wrightson WR, Wong SL, Edwards MJ, et al: Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 10:676-680, 2003
18. Sabel MS, Griffith K, Sondak VK, et al: Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 201:37-47, 2005
19. Thompson JF, McCarthy WH, Bosch CM, et al: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5:255-260, 1995
20. Krag DN, Meijer SJ, Weaver DL: Minimal-access surgery for staging of malignant melanoma. Arch Surg 130:654-660, 1995
21. Bilchik AJ, Giuliano A, Essner R, et al: Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 4:351-358, 1998
22. Haddad FF, Stall A, Messina J, et al: The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol 6:144-149, 1999
23. Cascinelli N, Belli F, Santinami M, et al: Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience. Ann Surg Oncol 7:469-474, 2000
24. Sabel MS, Gibbs JF, Cheney R, et al: Evolution of sentinel lymph node biopsy for melanoma at a National Cancer Institute-designated cancer center. Surgery 128:556-563, 2000
25. Starz H, Balda BR, Kramer KU, et al: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110-2121, 2001
26. Reeves ME, Delgado R, Busam KJ, et al: Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 10:27-31, 2003
27. Scolyer RA, Li LX, McCarthy SW, et al: Micro-morphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 122:532-539, 2004
28. Lee JH, Essner R, Torisu-ltakura H, et al: Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22: 3677-3684, 2004
29. Dewar DJ, Newell B, Green MA, et al: The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 22:3345-3349, 2004
30. Cascinelli N, Bombardieri E, Bufalino R, et al: Sentinel and nonsentinel node status in stage IB and II melanoma patients: Two-step prognostic indicators of survival. J Clin Oncol 24:4464-4471, 2006
31. Carlson GW, Murray DR, Lyles RH, et al: The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance? Ann Surg Oncol 10:575-581, 2003
32. Elias N, Tanabe KK, Sober AJ, et al: Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? Arch Surg 139:400-404, 2004
33. Govindarajan A, Ghazarian DM, McCready DR, et al: Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 33:906-912, 2006
34. Salti Gl, Das Gupta TK: Predicting residual lymph node basin disease in melanoma patients with sentinel lymph node metastases. Am J Surg 186:98-101, 2003
35. Starz H, Siedlecki K, Balda BR: Sentinel lymphonodectomy and s-classification: A successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 11:162S-168S, 2004
36. van Akkooi AC, de Wilt JH, Verhoef C, et al: Clinical relevance of melanoma micrometastases (< 0.1 mm) in sentinel nodes: Are these nodes to be considered negative? Ann Oncol 17:1578-1585, 2006
37. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, et al: Sentinel lymph node tumor load: An independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol 12:440-448, 2005
38. McMasters KM, Wong SL, Edwards MJ, et al: Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 9:137-141, 2002
39. Rossi CR, De Salvo GL, Bonandini E, et al; Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol 15:1202-1210, 2008
40. Koskivuo I, Talve L, Vihinen P, et al: Sentinel lymph node biopsy in cutaneous melanoma: A case-control study. Ann Surg Oncol 14:3566-3574, 2007
41. Page AJ, Carlson GW, Delman KA, et al: Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. Am Surg 73:674-678, 2007
42. Pearlman NW, McCarter MD, Frank M, et al: Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg 192:878-881, 2006
43. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
44. Gershenwald JE, Prieto V, Colome-Grimmer Ml, et al: The prognostic significance of microscopic tumor burden in 945 patients undergoing sentinel lymph node biopsy. Proc Am Soc Clin Oncol 19: 551a, 2000 (abstr 2169)
45. Gershenwald JE, Prieto VG, Johnson MM, et al: Heterogeneity of microscopic stage III melanoma in the SLN era: Implications for AJCC/UICC staging and future clinical trial design. 6th World Congress on Melanoma. Vancouver, BC, Canada, September 6-10, 2005 (abstr AB02657)
46. Andtbacka RHI, Bedrosian I, Ross Ml, et al: AJCC nodal factors and microscopic tumor burden predict recurrence in sentinel node positive stage III melanoma. 59th Annual Meeting, The Society of Surgical Oncology, San Diego, CA, March 23-26, 2006
47. Ranieri JM, Wagner JD, Azuaje R, et al: Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 9:975-981, 2002
48. Rousseau DLJr, Ross Ml, Johnson MM, et al: Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10:569-574, 2003
49. Gershenwald JE, Mansfield PF, Lee JE, et al: Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 7:160-165, 2000
50. Balch CM, Soong S-J, Bartoluccci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255-266, 1996
51. Veronesi U, Cascinelli N: Narrow excision (1-cm margin): A safe procedure for thin cutaneous melanoma. Arch Surg 126:438-441, 1991
52. Prieto VG, Clark SH: Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol 6:257-264, 2002
53. Lemeshow S, Hosmer D: Applied logistic regression. New York, NY, John Wiley and Sons, 2000
54. Gietema HA, Vuylsteke RJ, van Diest PJ, et al: Predicting nonsentinel lymph node involvement in stage l/ll melanoma. Ann Surg Oncol 10:993, 2003
55. Shaw HM, Thompson JF: Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 9:934, 2002
56. Wong SL, Morton DL, Thompson JF, et al: Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: A multi-institutional study. Ann Surg Oncol 13:809-816, 2006
57. Morton DL, Thompson JF, Cochran AJ, et al: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307-1317, 2006
58. Morton DL: Sentinel node mapping and an International Sentinel Node Society: Current issues and future directions. Ann Surg Oncol 11:137S-143S, 2004